



January 27, 2016

Veracyte to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th 2016 at 11:05 a.m. ET in New York, NY.

The live audio webcast from the Leerink Conference and subsequent replay may be accessed by visiting Veracyte's website at <http://investor.veracyte.com>. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.

In addition, Shelly Guyer, chief financial officer, and Chris Hall, chief operating officer, will participate in one-on-one meetings with investors at the 2016 BTIG Snowbird MedTech Conference on Thursday, February 25th in Snowbird, UT.

About Veracyte

Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma Thyroid FNA Analysis centers on the proprietary Afirma® Gene Expression Classifier and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for nearly 175 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. Veracyte is developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc.

Â

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/veracyte-to-participate-in-two-upcoming-investor-conferences-300208728.html>

SOURCE Veracyte

News Provided by Acquire Media